June 15th, 2011
Johnson & Johnson Steps Out of the Stent Market
Larry Husten, PHD
Johnson & Johnson announced today that it is exiting the stent business. The company will discontinue development of its Nevo sirolimus-eluting stent and will end sales of its Cypher family of stents by the end of the year. The company was the manufacturer of both the first stent, the Palmaz-Schatz stent, in the 1990s and […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?